Celecoxib + Chemotherapy for Bladder Cancer
(BLAST Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byAihua Edward Yen, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Baylor College of Medicine

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.

Eligibility Criteria

This trial is for adults with localized, muscle-invasive bladder cancer who haven't had systemic chemotherapy. They need recent scans and tests showing good organ function, no severe neuropathy or uncontrolled illnesses, not pregnant/nursing, and can't be regularly using NSAIDs or have a history of significant bleeding or heart issues.

Inclusion Criteria

I can take care of myself and am up and about more than 50% of my waking hours.

Your blood tests must show: i. a certain amount of white blood cells, ii. a certain level of hemoglobin, and iii. a certain number of platelets.

My tumor is invasive, measures at least 10mm, or causes kidney swelling.

+9 more

Exclusion Criteria

I haven't had serious bleeding issues in the last 6 months.

You cannot have asthma that is sensitive to aspirin.

I haven't had a stroke, heart attack, or severe angina in the last 6 months.

+9 more

Participant Groups

The study is testing the effects of adding Celecoxib to standard chemotherapy (Cisplatin and Gemcitabine) on bladder cancer tissue. Researchers will compare gene expression in tumor samples taken before and after treatment to see how Celecoxib affects the cells.

1Treatment groups

Experimental Treatment

Group I: Celecoxib plus Gemcitabine/Cisplatin chemoExperimental Treatment3 Interventions

Celecoxib plus Gemcitabine/Cisplatin neoadjuvant chemotherapy

Cisplatin is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺 Approved in European Union as Platinol for: